onclive·May 6·1 min readsaveFour-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026May 6, 2026·read at onclive ↗SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.sourceReporting by onclive.read at onclive ↗sharecopy linkx / twitterlinkedinmore…
comments(0)
5-min edit window · permanent after that